What is a stock summary page? Click here for an overview.
Business Description
Molecular Partners AG
ISIN : US60853G1067
Share Class Description:
STU:6ML0: ADRDescription
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 61.15 | |||||
| Equity-to-Asset | 0.89 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | -0.05 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | 2.48 | |||||
| Beneish M-Score | -2.85 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -21.4 | |||||
| 3-Year EBITDA Growth Rate | 8.1 | |||||
| 3-Year EPS without NRI Growth Rate | 6.4 | |||||
| 3-Year FCF Growth Rate | 16 | |||||
| 3-Year Book Growth Rate | 5 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 21.52 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 100.15 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 41.28 | |||||
| 9-Day RSI | 37.09 | |||||
| 14-Day RSI | 36.74 | |||||
| 3-1 Month Momentum % | -7.56 | |||||
| 6-1 Month Momentum % | 5.26 | |||||
| 12-1 Month Momentum % | 44.74 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 14.31 | |||||
| Quick Ratio | 14.31 | |||||
| Cash Ratio | 13.86 | |||||
| Days Sales Outstanding | 153.46 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -4.5 | |||||
| Shareholder Yield % | -12.29 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -1231.73 | |||||
| Net Margin % | -1087.38 | |||||
| FCF Margin % | -1218.57 | |||||
| ROE % | -34.6 | |||||
| ROA % | -31.16 | |||||
| ROIC % | -802.6 | |||||
| 3-Year ROIIC % | -6.77 | |||||
| ROC (Joel Greenblatt) % | -1096.91 | |||||
| ROCE % | -33.42 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 23.71 | |||||
| PB Ratio | 0.94 | |||||
| Price-to-Tangible-Book | 0.91 | |||||
| EV-to-EBIT | 0.27 | |||||
| EV-to-EBITDA | 0.28 | |||||
| EV-to-Revenue | -2.91 | |||||
| EV-to-FCF | 0.26 | |||||
| Price-to-GF-Value | 1.62 | |||||
| Price-to-Net-Current-Asset-Value | 0.94 | |||||
| Price-to-Net-Cash | 0.97 | |||||
| Earnings Yield (Greenblatt) % | 374.34 | |||||
| FCF Yield % | -45.43 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Molecular Partners AG Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 5.171 | ||
| EPS (TTM) (€) | -1.672 | ||
| Beta | -0.21 | ||
| 3-Year Sharpe Ratio | -0.31 | ||
| 3-Year Sortino Ratio | -0.53 | ||
| Volatility % | 114.52 | ||
| 14-Day RSI | 36.74 | ||
| 14-Day ATR (€) | 0.234696 | ||
| 20-Day SMA (€) | 4.06 | ||
| 12-1 Month Momentum % | 44.74 | ||
| 52-Week Range (€) | 3.06 - 9.8 | ||
| Shares Outstanding (Mil) | 36.87 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Molecular Partners AG Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Molecular Partners AG Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Molecular Partners AG Frequently Asked Questions
What is Molecular Partners AG(STU:6ML0)'s stock price today?
The current price of STU:6ML0 is €3.64. The 52 week high of STU:6ML0 is €9.80 and 52 week low is €3.06.
When is next earnings date of Molecular Partners AG(STU:6ML0)?
The next earnings date of Molecular Partners AG(STU:6ML0) is 2025-06-07 Est..
Does Molecular Partners AG(STU:6ML0) pay dividends? If so, how much?
Molecular Partners AG(STU:6ML0) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers